EUCTR2004-000895-16-IT进行中（未招募）不适用
A multicenter, randomized, double-blind, placebocontrolled, parallel-group study to evaluate the effects ofaliskiren on proteinuria when added to standardized losartan therapy and optimal antihypertensive therapy inpatients with hypertension and Type 2 diabetes mellitus.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A multicenter, randomized, double-blind, placebocontrolledstudy, to assess the long term safety of 52weeks treatment with QVA149 (110µg indacaterol / 50µgglycopyrrolate) in patients with moderate to severe ChronicObstructive Pulmonary Disease (COPD)EUCTR2009-013235-38-LTovartis Pharma AG339
进行中（未招募）
1 期
A multicenter, randomized, double-blind, placebocontrolled study, to assess the long term safety of 52 weeks treatment with QVA149 (110µg indacaterol / 50µg glycopyrrolate) in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)EUCTR2009-013235-38-GBovartis Pharma Services AG
进行中（未招募）
不适用
A multicenter, randomized, double-blind, placebocontrolledstudy, to assess the long term safety of 52weeks treatment with QVA149 (110µg indacaterol / 50µgglycopyrrolate) in patients with moderate to severe ChronicObstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-013235-38-LVovartis Pharma AG339
Unknown
3 期
Efficacy, safety and tolerability of serelaxin when added to standardtherapy in Asian patients with acute heart failure (AHF)CTRI/2016/05/006952ovartis Healthcare Pvt Ltd1,520
进行中（未招募）
不适用
A multicenter, randomized, double-blind, placebocontrolledstudy, to assess the long term safety of 52weeks treatment with QVA149 (110µg indacaterol / 50µgglycopyrrolate) in patients with moderate to severe ChronicObstructive Pulmonary Disease (COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDEUCTR2009-013235-38-HUovartis Pharma AG339